Silymarin induces cell cycle arrest and apoptosis in ovarian cancer cells

Li Fan1, Yalin Ma1, Ying Liu1

  • 1Department of Obstetrics and Gynecology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China.

Insights

Silymarin, a milk thistle extract, effectively inhibits ovarian cancer cell growth by halting cell cycle progression and inducing apoptosis. This natural compound shows potential for ovarian cancer prevention and treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Silymarin, a flavonoid from milk thistle, exhibits anti-cancer properties against various epithelial cancers.
  • Ovarian cancer remains a significant health concern with a need for novel therapeutic strategies.

Purpose of the Study:

  • To investigate the anti-cancer effects of silymarin on human ovarian cancer cell lines (A2780s and PA-1).
  • To elucidate the mechanisms underlying silymarin's action, including cell cycle regulation and apoptosis induction.

Main Methods:

  • Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
  • Cell cycle progression, apoptosis, and mitochondrial membrane potential were analyzed via flow cytometry and specific staining assays.
  • Protein expression levels (p53, p21, p27, CDK2, Bax, Bcl-2, caspases) and enzyme activities were determined using Western blotting and Caspase-Glo assays.

Main Results:

  • Silymarin suppressed ovarian cancer cell growth in a dose- and time-dependent manner.
  • Silymarin induced G1/S phase cell cycle arrest by modulating p53, p21, p27, and CDK2 expression.
  • Silymarin triggered apoptosis through mitochondrial pathway activation, evidenced by decreased mitochondrial membrane potential, cytochrome C release, altered Bax/Bcl-2 ratio, and caspase-9/-3 activation.

Conclusions:

  • Silymarin demonstrates significant anti-cancer activity against human ovarian cancer cells.
  • Silymarin's mechanisms involve cell cycle arrest and apoptosis induction, suggesting its potential as a therapeutic agent for ovarian cancer.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K